Bellevue Group AG Sells 1,397 Shares of Illumina, Inc. (NASDAQ:ILMN)

Bellevue Group AG decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,596 shares of the life sciences company’s stock after selling 1,397 shares during the period. Bellevue Group AG’s holdings in Illumina were worth $5,987,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Bouvel Investment Partners LLC increased its position in shares of Illumina by 1.3% during the first quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock worth $899,000 after acquiring an additional 84 shares in the last quarter. STF Management LP increased its position in shares of Illumina by 3.5% during the fourth quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock worth $368,000 after acquiring an additional 90 shares in the last quarter. Global Retirement Partners LLC increased its position in shares of Illumina by 12.3% during the first quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock worth $118,000 after acquiring an additional 94 shares in the last quarter. Gulf International Bank UK Ltd boosted its holdings in Illumina by 0.7% during the first quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock worth $1,862,000 after purchasing an additional 98 shares during the last quarter. Finally, Clear Creek Financial Management LLC boosted its holdings in Illumina by 6.3% during the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock worth $236,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ILMN. Stephens restated an “overweight” rating and set a $170.00 target price on shares of Illumina in a report on Wednesday, July 10th. Citigroup upgraded shares of Illumina from a “neutral” rating to a “buy” rating and set a $140.00 target price for the company in a report on Wednesday, July 10th. Robert W. Baird increased their target price on shares of Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Barclays increased their price target on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research note on Wednesday, April 10th. Finally, StockNews.com started coverage on shares of Illumina in a research note on Sunday, June 30th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $158.57.

Illumina Stock Performance

NASDAQ:ILMN traded up $3.13 during mid-day trading on Friday, reaching $120.43. 1,467,725 shares of the company’s stock were exchanged, compared to its average volume of 1,755,526. Illumina, Inc. has a one year low of $89.00 and a one year high of $195.64. The firm has a market capitalization of $19.18 billion, a PE ratio of -14.78 and a beta of 1.15. The business’s fifty day simple moving average is $109.87 and its two-hundred day simple moving average is $124.08. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period last year, the firm earned $0.08 earnings per share. Illumina’s revenue for the quarter was down 1.0% compared to the same quarter last year. Analysts anticipate that Illumina, Inc. will post 1.38 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.